natgillin/translations-raw huggingface dataset:
Use in patients with more severe renal impairment is contraindicated (see section 4.3). 
Uporaba pri bolnikih s hujšo ledvično okvaro je kontraindicirana (glejte poglavje 4.3).
To avoid the possibility of interactions with other medicines please tell your doctor or hospital pharmacist or nurse if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. 
Da bi se izognili morebitnemu medsebojnemu delovanju z drugimi zdravili, obvestite svojega zdravnika, bolnišničnega farmacevta ali medicinsko sestro, če jemljete ali ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Eptifibatide -treated patients who had a prothrombin time (PT) > 14.5 seconds and received warfarin concomitantly did not appear to be at an increased risk of bleeding. 
Tudi pri z eptifibatidom zdravljenih bolnikih, ki so imeli protrombinski čas (PČ) > 14,5 sekund in so sočasno prejemali varfarin, ni kazalo, da bi bili bolj ogroženi zaradi krvavitev.
There are no adequate data from the use of eptifibatide in pregnant women. 
Ni zadostnih podatkov o uporabi eptifibatida pri nosečnicah.
− if you have been treated with another medicine of the same type as Eptifibatide Accord. 
− če ste bili zdravljeni z drugim zdravilom iste vrste, kot je Eptifibatide Accord.
Results on the primary endpoint were principally attributed to the occurrence of myocardial infarction. 
Izsledki za primarni končni cilj so bili pripisani predvsem pojavu miokardnega infarkta.
It should be administered by specialist physicians experienced in the management of acute coronary syndromes. 
Dajati ga morajo specialisti z izkušnjami na področju zdravljenja akutnih koronarnih sindromov.
The 180/1.3 arm was stopped after an interim analysis, as prespecified in the protocol, when the two active-treatment arms appeared to have a similar incidence of bleeding. 
Krak 180/1,3 te študije so ustavili po vmesni analizi, kot je bilo vnaprej določeno v protokolu, ker je kazalo, da je incidenca krvavitev v obeh krakih z aktivnim zdravljenjem podobna.
These are absolute reporting frequencies without taking into account placebo rates. 
To so absolutne zabeležene pogostnosti, neupoštevaje deleže pri placebu.
In ESPRIT, bleeding events were reported at 48 hours, and non-bleeding events were reported at 30 days. 
V študiji ESPRIT so krvavitvene dogodke zabeležili po 48 urah, nekrvavitvene pa po 30 dneh.
Potentially, an overdose of eptifibatide could result in bleeding. 
Preveliko odmerjanje eptifibatida bi lahko povzročilo krvavitve.
− Eptifibatide Accord is not intended for use in children or adolescents less than 18 years of age. 
− Zdravilo Eptifibatide Accord ni namenjeno za uporabo pri otrocih in mladostnikih do 18. leta starosti.
Other potential bleeding sites such as central and peripheral nervous system and retroperitoneal sites, must be carefully considered too. 
Skrbno preglejte tudi druga možna mesta krvavitev, npr. osrednje in periferno živčevje ter retroperitonealni prostor.
Specifically, no patients experienced an intracranial bleed. 
Noben bolnik ni imel intrakranialne krvavitve.
Unlike the approved posology in the EU, all patients in this trial were administered a double bolus before the infusion (see section 5.1). 
V nasprotju z odmerjanjem, odobrenim v EU, so vsi bolniki v tej študiji pred infundiranjem dobili dvojni bolus (glejte poglavje 5.1).
− if you had a major operation or severe injury during the past 6 weeks. 
− če ste imeli v zadnjih 6 tednih večjo operacijo ali hudo poškodbo;
The reduction in the incidence of endpoint events in patients receiving eptifibatide appeared early during treatment (within the first 72-96 hours) and this reduction was maintained through 6 months, without any significant effect on mortality. 
Zmanjšanje incidence pojavov končnega cilja pri bolnikih, ki so prejemali eptifibatid, se je pojavilo že zgodaj med zdravljenjem (v roku prvih 72 do 96 ur) in je bilo prisotno vseh 6 mesecev, brez bistvenega učinka na umrljivost.
319, Pinner Road North Harrow Middlesex HA1 4HF United Kingdom 
319, Pinner Road North Harrow Middlesex HA1 4HF Velika Britanija
Administration of eptifibatide by intravenous bolus and infusion causes up to a 5-fold increase in bleeding time. 
Uporaba eptifibatida v intravenskem bolusu in infuziji povzroči do 5-kratno podaljšanje časa krvavitve.
When administered alone, eptifibatide has no measurable effect on prothrombin time (PT) or activated partial thromboplastin time (aPTT). 
Eptifibatid, uporabljen sam, nima merljivega učinka na protrombinski čas (PČ) ali aktivirani parcialni tromboplastinski čas (aPTČ).
Eptifibatide Accord is also intended for concurrent use with acetylsalicylic acid, as it is part of standard management of patients with acute coronary syndromes, unless its use is contraindicated. 
Zdravilo Eptifibatide Accord je namenjeno tudi za sočasno uporabo z acetilsalicilno kislino, ker je del standardne sheme vodenja bolnikov z akutnim koronarnim sindromom, če zanj ni kontraindikacij.
319, Pinner Road, Harrow Middlesex HA1 4HF United Kingdom 
319, Pinner Road, Harrow Middlesex HA1 4HF Velika Britanija
Because of its short half-life and rapid clearance, the activity of eptifibatide may be halted readily by discontinuing the infusion. 
Zaradi kratkega razpolovnega časa in hitrega očistka eptifibatida pa lahko njegovo delovanje hitro ustavite s prekinitvijo infuzije.
In a post hoc analysis of the EARLY ACS trial the risk benefit of dose reduction in patients with moderate renal impairment is inconclusive. 
V post hoc analizi preskušanja EARLY ACS razmerje koristi in tveganj znižanja odmerka pri bolnikih z zmerno okvaro ledvic ni omogočilo dokončnih sklepov.
Eptifibatide Accord is not compatible with furosemide. 
Zdravilo Eptifibatide Accord ni združljivo s furosemidom.
Shock, hypotension, phlebitis. 
Pogosti šok, hipotenzija, flebitis.
An increased risk of bleeding may also be observed in patients who receive early administration of eptifibatide (e.g. upon diagnosis) compared to receiving it immediately prior to PCI, as seen in the Early ACS trial. 
Večje tveganje krvavitev se lahko pojavi tudi pri bolnikih, ki prejmejo eptifibatid zgodaj (npr. ob postavitvi diagnoze), v primerjavi s tistimi, ki ga prejmejo tik pred perkutanim koronarnim posegom, kot je pokazala študija Early ACS.
No genotoxic effects were observed with eptifibatide. 
Genotoksičnih učinkov pri eptifibatidu niso opažali.
Unlike the approved posology in the EU, the study used a double bolus of study drug (separated by 10 minutes) before the infusion. 
V nasprotju z odmerjanjem, odobrenim v EU, so v študiji pred infundiranjem uporabili dvojni bolus raziskovanega zdravila (v presledku 10 minut).
During treatment with eptifibatide there is a significant increase in bleeding rates, especially in the femoral artery area, where the catheter sheath is introduced. 
Med zdravljenjem z eptifibatidom se znatno poveča pogostnost krvavitev, zlasti v predelu femoralne arterije, kjer se vstavi vodilo katetra.
It is contraindicated in patients with clinically significant hepatic impairment. 
Zdravilo je kontraindicirano pri bolnikih s klinično pomembno jetrno okvaro.
In healthy subjects, renal excretion accounted for approximately 50 % of total body clearance; approximately 50 % of the amount cleared is excreted unchanged. 
Pri zdravih osebah gre približno 50 % celotnega telesnega očistka na račun ledvičnega izločanja, približno 50 % očiščene količine pa se izloči v nespremenjeni obliki.
The mechanism, whether immune- and/or non-immune-mediated, by which eptifibatide may induce thrombocytopenia is not fully understood. 
Mehanizem - imunski in/ali neimunski - po katerem lahko eptifibatid povzroči trombocitopenijo, ni povsem pojasnjen.
Compared to placebo, eptifibatide administered as 180/2.0 significantly reduced the incidence of the primary endpoint events (table 1): this represents around 15 events avoided for 1,000 patients treated: 
V primerjavi s placebom je eptifibatid uporabljen po shemi 180/2,0 statistično značilno zmanjšal incidenco pojavov primarnega končnega cilja (Tabela 1): to pomeni približno 15 preprečenih pojavov na 1.000 zdravljenih bolnikov.
GUSTO severe/life threatening bleeding was uncommon and comparable in both treatment groups (0.8 %). 
Hude/smrtno nevarne krvavitve po GUSTO so bile občasne in v obeh terapevtskih skupinah primerljive (0,8 %).
The data sources used to determine adverse reaction frequency descriptors included two phase III clinical studies (PURSUIT and ESPRIT). 
Klinične raziskave Vir podatkov za ugotovitev pogostnosti neželenih učinkov sta dve klinični študiji III. faze (PURSUIT
Emergency or semi-elective surgery 
Urgentno ali polurgentno kirurško zdravljenje
Monitor these patients closely with regard to bleeding. 
Takšne bolnike morate skrbno spremljati zaradi možnih krvavitev.
This increase is readily reversible upon discontinuation of the infusion with bleeding times returning towards baseline in approximately 6 (2-8) hours. 
To podaljšanje je hitro reverzibilno po prenehanju infuzije in čas krvavitve se vrne proti izhodiščni vrednosti v približno 6 (od 2 do 8) urah.
Eptifibatide Accord is not usually recommended for use during pregnancy. 
Zdravila Eptifibatide Accord po navadi ni priporočljivo uporabljati med nosečnostjo.
Eptifibatide Accord infusion should be stopped immediately if circumstances arise that necessitate thrombolytic therapy or if the patient must undergo an emergency CABG surgery or requires an intraortic balloon pump. 
Infuzijo zdravila Eptifibatide Accord morate nemudoma ustaviti, če nastopijo okoliščine, ki zahtevajo trombolitično zdravljenje, če mora bolnik na nujen koronarni premostitveni poseg ali če potrebuje intraaortno balonsko črpalko.
− if you have or have had severe hypertension (high blood pressure). 
− če imate ali ste kdaj imeli močno zvišan krvni tlak (hipertenzijo);
Cardiac arrest, congestive heart failure, atrial fibrillation, hypotension, and shock, which are commonly reported events from the PURSUIT trial, were events related to the underlying disease. 
Zastoj srca, kongestivno srčno popuščanje, atrijska fibrilacija, hipotenzija in šok, pogosto zabeleženi dogodki v študiji PURSUIT, so bili povezani z osnovno boleznijo.
Changes during eptifibatide treatment result from its known pharmacological action, i.e., inhibition of platelet aggregation. 
Spremembe med zdravljenjem z eptifibatidom nastanejo zaradi njegovega znanega farmakološkega delovanja, tj. zavrtja agregacije trombocitov.
Ask your hospital pharmacist how to throw away medicines you no longer use. 
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte bolnišničnim farmacevtom.
Eptifibatide Accord is chemically and physically compatible with 0.9 % sodium chloride solution for infusion and with dextrose 5 % in Normosol R with or without potassium chloride up to 92 hours when stored at 20-25°C. 
Zdravilo Eptifibatide Accord je kemijsko in fizikalno združljivo z 0,9 % raztopino natrijevega klorida za infundiranje in s 5 % dekstrozo v Normosolu R, z ali brez kalijevega klorida, do 92 ur pri shranjevanju pri temperaturi 20 °C - 25 °C.
In the PURSUIT trial, there were 9 patients who received bolus and/or infusion doses more than double the recommended dose, or who were identified by the investigator as having received an overdose. 
9 bolnikov takih, ki so prejeli bolusni in/ali infuzijski odmerek, ki je bil več kot dvakrat večji od priporočenega odmerka, oz. ki so jih raziskovalci označili kot prejemnike prevelikega odmerka.
However, treatment with eptifibatide was associated with antibodies that recognise GPIIb/IIIa occupied by eptifibatide, suggesting an immune-mediated mechanism. 
Vendar je bilo zdravljenje z eptifibatidom povezano s protitelesi, ki prepoznajo z eptifibatidom zasedeni GPIIb/IIIa, in to kaže na imunski mehanizem.
Consequently the use of Eptifibatide Accord is not recommended in these circumstances (see section 4.5). 
Uporaba zdravila Eptifibatide Accord pri takšnih bolnikih torej ni priporočljiva (glejte poglavje 4.5).
Bleeding is most common at the arterial access site in patients undergoing percutaneous arterial procedures. 
Krvavitve se najpogosteje pojavijo na mestu arterijskega dostopa pri bolnikih, pri katerih izvajamo perkutani arterijski poseg.
If serious bleeding occurs that is not controllable with pressure, the Eptifibatide Accord infusion should be stopped immediately and any unfractionated heparin that is given concomitantly. 
Če se pojavi hujša krvavitev, ki je ni mogoče obvladati s pritiskom, morate nemudoma ustaviti infuzijo zdravila Eptifibatide Accord in morebitno sočasno uporabo nefrakcioniranega heparina.
The primary endpoint of the study was the occurrence of death from any cause or new myocardial infarction (MI) (evaluated by a blinded Clinical Events Committee) within 30 days of randomisation. 
Primarni končni cilj študije je bila smrt iz kakršnegakoli vzroka ali nov miokardni infarkt (MI) (po oceni Komisije za klinične pojave (KKP), ki ni imela podatka o skupini) v roku 30 dni od randomizacije.
These studies revealed no evidence of impaired fertility or harm to the foetus due to eptifibatide. 
Te študije niso pokazale nobenih znakov zmanjšane plodnosti ali škodljivih učinkov eptifibatida na plod.
Eptifibatide Accord should not be used during pregnancy unless clearly necessary. 
Zdravila Eptifibatide Accord ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
It is used in adults with manifestation of severe coronary insufficiency defined as spontaneous and recent chest pain with electrocardiographic abnormalities or biological changes. 
Uporablja se pri odraslih z znaki hude koronarne insuficience, ki je opredeljena kot nedavna spontana bolečina v prsih z nepravilnostmi v EKG ali biološkimi spremembami.
Cardiac arrest, ventricular fibrillation, ventricular tachycardia, congestive heart failure, atrioventricular block, atrial fibrillation. 
Pogosti srčni zastoj, ventrikularna fibrilacija, ventrikularna tahikardija, kongestivno srčno popuščanje, atrioventrikularni blok, atrijska fibrilacija;
PURSUIT was conducted at a time when the standard of care of managing acute coronary syndromes was different from that of present times in terms of thienopyridine use and the routine use of intracoronary stents. 
Študija PURSUIT je bila opravljena v času, ko je bilo standardno zdravljenje za obvladovanje akutnih koronarnih sindromov drugačno od trenutnega, kar zadeva uporabo tienopiridina in rutinske uporabe intrakoronarnih žilnih opornic.
Any unused medicine after opening should be thrown away. 
Morebitni neporabljeni ostanek zdravila po odprtju morate zavreči.
Thus, although eptifibatide can be dialysed, the need for dialysis is unlikely. 
Čeprav eptifibatid lahko odstranimo iz telesa z dializo, je torej malo verjetno, da bo ta potrebna.
Teratology studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits at total daily doses of up to 36 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis). 
Teratološke študije so bile opravljene s kontinuirano intravensko infuzijo eptifibatida pri brejih podganah s skupnimi dnevnimi odmerki do 72 mg/kg/dan (približno 4-kratni priporočeni največji dnevni odmerek za človeka na podlagi telesne površine) in pri brejih kunčjih samicah s skupnimi dnevnimi odmerki do 36 mg/kg/dan (približno 4-kratni priporočeni največji dnevni odmerek za človeka na podlagi telesne površine).
The primary endpoint of the trial was death (D), MI, urgent target vessel revascularisation (UTVR), and acute antithrombotic rescue with GP IIb/IIIa inhibitor therapy (RT) within 48 hours of randomisation. 
Primarni končni cilj študije je vključeval smrt (D), miokardni infarkt (MI), urgentno revaskularizacijo prizadete žile (UTVR) in akutno antitrombotično terapijo z zaviralcem GP IIb/IIIa) (RT) v roku 48 ur po randomizaciji.
Bleeding events were more frequent in patients receiving concurrent heparin while undergoing PCI, when ACT exceeded 350 seconds (see section 4.4, heparin use). 
Krvavitve so bile pogostejše pri bolnikih, ki so med perkutano koronarno intervencijo sočasno dobivali heparin, če je AČS presegal 350 sekund (glejte poglavje 4.4, Uporaba heparina).
• either ST-segment changes: ST depression > 0.5 mm of less than 30 minutes or persistent ST elevation > 0.5 mm not requiring reperfusion therapy or thrombolytic agents, T-wave inversion (> 1 mm), 
• bodisi spremembe spojnice ST: znižanje spojnice ST za > 0,5 mm za manj kot 30 minut ali trdovratno zvišanje spojnice ST za > 0,5 mm, ki ni zahtevalo reperfuzijske terapije ali trombolitičnih zdravil, inverzijo vala T (> 1 mm), • ali povečanje vrednosti CK-MB.
ESPRIT trial 
Študija ESPRIT
Before using, inspect the vial contents. 
Pred uporabo preglejte vsebino viale.
Major bleeding was also very common and reported more frequently with eptifibatide than with placebo in the PURSUIT study (> 1/10 or 10.8 % versus 9.3 %), but it was infrequent in the vast majority of patients who did not undergo CABG within 30 days of inclusion in the study. 
Tudi večje krvavitve so bile v študiji PURSUIT zelo pogoste in pogosteje opisane med zdravljenjem z eptifibatidom kot s placebom (> 1/10 ali 10,8 % v primerjavi z 9,3 %), a niso bile pogoste pri veliki večini bolnikov, pri katerih ni bil narejen obvod koronarne arterije v 30 dneh od vključitve v študijo.
If either a confirmed platelet decrease to < 100,000/mm3 or acute profound thrombocytopenia is observed, discontinuation of each treatment medication having known or suspected thrombocytopenic effects, including eptifibatide, heparin and clopidogrel, should be considered immediately. 
Če se pojavi potrjeno zmanjšanje števila trombocitov na < 100.000 celic/mm3, ali akutna izrazita trombocitopenija, je treba nemudoma prekiniti uporabo zdravil, za katere je znano ali se domneva, da učinkujejo trombocitopenično, vključno z eptifibatidom, heparinom in klopidogrelom.
The majority of adverse reactions experienced by patients treated with eptifibatide were generally related to bleeding or to cardiovascular events that occur frequently in this patient population. 
4.8 Neželeni učinki Večina neželenih učinkov, ki so jih imeli bolniki, zdravljeni z eptifibatidom, je bila praviloma povezana s krvavitvami ali kardiovaskularnimi pojavi, ki so v tej populaciji bolnikov tudi sicer pogosti.
What Eptifibatide Accord is and what it is used for What you need to know before you are given Eptifibatide Accord How to use Eptifibatide Accord 
Kaj je zdravilo Eptifibatide Accord in za kaj ga uporabljamo Kaj morate vedeti, preden boste dobili zdravilo Eptifibatide Accord Kako uporabljati zdravilo Eptifibatide Accord
ESPRIT: This was a double-blind, multicentre, randomized, parallel-group, placebo-controlled trial evaluating the safety and efficacy of eptifibatide therapy in patients scheduled to undergo nonemergent percutaneous coronary intervention (PCI) with stent implantation. 
ESPRIT: To je bila dvojno slepa, multicentrična, randomizirana, s placebom kontrolirana študija vzporednih skupin za oceno varnosti in učinkovitosti zdravljenja z eptifibatidom pri bolnikih s predvideno neurgentno perkutano koronarno intervencijo (PCI) z namestitvijo žilne opornice.
A total of 1,250 patients underwent PCI within 72 hours after randomisation, in which case they received intravenous unfractionated heparin to maintain an activated clotting time (ACT) of 300-350 seconds. 
V 72 urah po randomizaciji so perkutani koronarni poseg opravili pri skupaj 1.250 bolnikih, ki so jim v tem primeru intravensko dajali nefrakcioniran heparin, da so aktivirani čas strjevanja (AČS) ves čas ohranjali med 300 in 350 sekundami.
During treatment with eptifibatide in this study, minor bleeding was a very common complication (> 1/10, or 13.1 % for eptifibatide versus 7.6 % for placebo). 
Manjše krvavitve so bile v tej študiji med zdravljenjem z eptifibatidom zelo pogost zaplet (> 1/10 ali 13,1 % za eptifibatid v primerjavi s 7,6 % za placebo).
Administration of eptifibatide is associated with an increase in major and minor bleeding as classified by the criteria of the TIMI study group. 
Uporabo eptifibatida spremlja večja pogostnost večjih in manjših krvavitev, razvrščenih po merilih raziskovalne skupine TIMI.
Unfractionated heparin was administered intravenously or subcutaneously at the physician's discretion, most commonly as an intravenous bolus of 5,000 U followed by a continuous infusion of 1,000 U/h. 
Nefrakcioniran heparin so jim dajali intravensko ali subkutano po presoji zdravnika, najpogosteje v obliki intravenskega bolusa po 5.000 enot/h, ki mu je sledila kontinuirana infuzija po 1.000 enot/h.
− Eptifibatide Accord is recommended for use only in adult, hospitalised patients in coronary care units. 
− Zdravilo Eptifibatide Accord priporočamo za uporabo le pri odraslih bolnikih, hospitaliziranih na bolnišničnih koronarnih oddelkih.
− Before and during your treatment with Eptifibatide Accord, samples of your blood will be tested as a safety measure to limit the possibility of unexpected bleeding. 
− Pred in med zdravljenjem z zdravilom Eptifibatide Accord bodo pri vas opravili krvne preiskave kot varnostni ukrep za zmanjšanje možnosti za pojav nepričakovanih krvavitev.
If the platelet count falls below 100,000/mm3, further platelet counts are required to rule out pseudothrombocytopenia. 
Če se število trombocitov zmanjša pod 100.000 celic/mm3, bodo potrebne dodatne določitve števila trombocitov, da izključite psevdotrombocitopenijo.
The ESPRIT trial used a simplified regimen of heparin during PCI that consisted of an initial bolus of 60 units/kg, with a target ACT of 200 - 300 seconds. 
V študiji ESPRIT so uporabili poenostavljen režim odmerjanja heparina ob perkutanem koronarnem posegu, ki je sestojil iz začetnega bolusa 60 enot/kg, tarčni AČS pa je bil med 200 in 300 sekund.
The need for blood transfusions was increased modestly by eptifibatide treatment (11.8 % versus 9.3 % for placebo). 
Zdravljenje z eptifibatidom je zmerno povečalo potrebo po transfuzijah krvi (11,8 % v primerjavi z 9,3 % pri placebu).
Minor bleeding was defined in the PURSUIT trial as spontaneous gross haematuria, spontaneous haematemesis, observed blood loss with a haemoglobin decrease of more than 3 g/dl, or a haemoglobin decrease of more than 4 g/dl in the absence of an observed bleeding site. 
Kot manjše krvavitve so bile v študiji PURSUIT opredeljene spontana močna hematurija, spontana hematemeza, opažena izguba krvi z znižanjem hemoglobina za več kot 3 g/dl, ali znižanje hemoglobina za več kot 4 g/dl brez opaženega mesta krvavitve.
Frequencies are defined as very common (≥ 1/10); common (≥ 1/100 to< 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to 
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do 1/100), redki (≥ 1/10.000 do
The effect of eptifibatide is observed immediately after administration of a 180 microgram/kg intravenous bolus. 
Učinek eptifibatida je opazen takoj po dajanju intravenskega bolusa 180 mikrogramov/kg.
Not relevant, as Eptifibatide Accord is intended for use only in hospitalised patients. 
Podatek ni potreben, ker je zdravilo Eptifibatide Accord namenjeno samo zdravljenju hospitaliziranih bolnikov.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC (IZDELOVALCI) ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
It is not recommended for use in children and adolescents below 18 years of age, due to a lack of data on safety and efficacy. 
Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
What Eptifibatide Accord is and what it is used for 
Kaj je zdravilo Eptifibatide Accord in za kaj ga uporabljamo